Recent health news includes Amgen's launch of an Eylea biosimilar in the U.S., Slovakia's bird flu outbreak, and China's ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

A Maryland drug affordability board can move forward with a plan to cap how much the state and local governments pay for ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

Global Thrombocytopenia Treatment IndustryThe global Thrombocytopenia Treatment Market is projected to experience significant ...

The global Oncolytic Virus Cancer Therapy (OVT) market is expected to be valued at USD 22.86 million in 2023, with ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Amgen (AMGN – Research Report) and keeping the price target at ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $383.00. Yaron ...

With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, ...